| P2093 | author name string | Longbang Chen | |
| | Guichun Huang | |
| | Shujing Shi | |
| | Leilei Tao | |
| P2860 | cites work | From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors | Q26865532 |
| | Cancer statistics, 2013 | Q27860762 |
| | Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. | Q30469815 |
| | Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation | Q33995820 |
| | Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models | Q34782683 |
| | Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells | Q35093618 |
| | Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization | Q36178042 |
| | Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 |
| | Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma | Q36744566 |
| | Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors | Q37895924 |
| | Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? | Q38026626 |
| | Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model | Q39650152 |
| | A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission | Q40280519 |
| | Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape | Q42144023 |
| | Immunohistochemical detection of tumour hypoxia | Q43230091 |
| | Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma | Q44239994 |
| | Changing the Tumor Microenvironment: New Strategies for Immunotherapy | Q45880727 |
| | Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models | Q46659724 |
| | Researche advances on CIK cells and their clinical use in lung cancer | Q55504567 |
| | Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma | Q82776265 |
| P433 | issue | 1 | |
| P921 | main subject | bevacizumab | Q413299 |
| | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 777 | |
| P577 | publication date | 2013-11-24 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models | |
| P478 | volume | 31 | |